Oxalipatin-Based Chemotherapy for Grade 3 Neuroendocrine Carcinoma after Failure of Platinum- Based Chemotherapy Abstract #714

Introduction: Cisplatin/etoposide regimen is the recommended first line treatment for poorly differentiated grade 3 neuroendocrine carcinoma (G3-NEC). There is no standard second line.
Aim(s): We analyzed the antitumor efficacy of oxaliplatin-based chemotherapy (Ox-bC) in G3-NEC patients (pts).
Materials and methods: This is a single center retrospective analysis of consecutive G3-NEC pts treated with Ox-bC between December 2003 and June 2012. Primary endpoint was progression-free survival (PFS) and secondary endpoints were overall survival (OS), response rate (RR) and safety.
Conference: 10th Annual ENETS Conference (2013)
Category: Medical treatment - Chemotherapy
Presenting Author: Dr Julien Hadoux

To read results and conclusion, please login ...

Further abstracts you may be interested in

#117 Synchronous appendiceal neuroendocrine carcinoma and mucinous cystadenocarcinoma: a case report
Introduction: Appendiceal tumors with histological features of both carcinoids and adenocarcinomas are very rare. Carcinomas of the appendix are usually mucinous adenocarcinomas with a tendency to produce peritoneal pseudomyxoma and without metastatic spread until late in the disease course. Carcinoid tumors of the appendix are a common incidental finding.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Sanja Ognjanovic
#144 Oxaliplatin-based chemotherapy in patients with advanced neuroendocrine carcinoma: an Italian retrospective multicenter analysis
Introduction: Conventional chemotherapy does not have a well-defined role in well/moderately differentiated (WD) neuroendocrine carcinomas (NECs). Various regimens were evaluated. Cisplatin or carboplatin combined with etoposide are usually indicated in poorly differentiated (PD) NECs. Some evidence exists for oxaliplatin activity in WD and PD NECs, combined with capecitabine or gemcitabine.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Francesca Spada
#507 Are all Metastatic Grade 3 WHO 2010 Neuroendocrine Carcinoma Poorly Differentiated?
Introduction: The WHO classification 2010 for neuroendocrine tumors (NET) defines poorly differentiated neuroendocrine carcinomas (NEC) as grade 3 (G3) according to mitoses> 20/10 HPF and/or Ki-67>20%.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr Fritz-Line Vélayoudom-Céphise
#668 Analysis of the Undifferentiated Neuroendocrine Carcinomas (grade 3) from the Czech Neuroendocrine Registry
Introduction: GEP NETs WHO classification 2010 describes well-differentiated tumors grade 1 and grade 2 and neuroendocrine carcinomas grade 3 with high mitotic index over 20 mitoses /10 HPF or Ki 67 over 20%. Pulmonary neuroendocrine tumor classification 2004 describes typical and atypical carcinoid tumor and small-cell and large-cell neuroendocrine carcinomas with mitotic index over 10 mitoses/ 10 HPF.
Conference: 10th Annual ENETS Conference (2013)
Category: Pathology, grading, staging
Presenting Author: M.D., MBA Eva Sedlackova
#867 Mixed Adenoneuroendocrine Carcinoma (MANECs): A Rare and Challenging Subgroup of Neuroendocrine Neoplasia
Introduction: Mixed Adenoneuroendocrine Carcinomas (MANECs) are rare entities in which at least 30% of neoplastic cells are neuroendocrine in nature (WHO 2010 classification). They result either from two independent lesions that merge together or are unique lesions with different cell populations intermingled.
Conference: 11th Annual ENETS Conference (2014)
Category: Pathology, grading, staging
Presenting Author: Dr Conor Mosli Lynch